About Stemson Therapeutics
Stemson Therapeutics is a company based in San Diego (United States) founded in 2019 by Geoff Hamilton and Alexey Terskikh. Stemson Therapeutics has raised $22.5 million across 3 funding rounds from investors including AbbVie, Allergan and DCVC. Stemson Therapeutics operates in a competitive market with competitors including Ardelyx, Blue Rock Therapeutics, DermBiont, Aspen Neuroscience and Inozyme Pharma, among others.
- Headquarter San Diego, United States
- Founders Geoff Hamilton, Alexey Terskikh
- SectorsHealthcare
- Email••••••••
- Website stemsontx.com
- Social LinkedIn
- Total Equity Funding$22.5M (USD)
in 3 rounds
- Latest Funding Round$15M (USD), Series A
Jul 2021
- InvestorsAbbVie
& 5 more
Funding Insights of Stemson Therapeutics
Stemson Therapeutics has successfully raised a total of $22.5M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $15 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $22.5M
- Total Rounds 3
- Last Round Series A — $15M
- Investors Count 6
All 3 funding rounds of Stemson Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $15M | Series A | – | DCVC | |
| Sep 2020 | $7.5M | Seed | – | Allergan Aesthetics, Fortunis Capital | – |
| Jun 2019 | – | Seed | – | Allergan | – |
6 investors in total: 6 institutional.
Investors in Stemson Therapeutics
Stemson Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie, Allergan and DCVC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on multiple sectors | – | dcvc.com | Palo Alto, United States | |
Early-stage VC firm focused on life science startups | – | genoavc.com | San Francisco, United States | |
Fortunis Capital is engaged in impact-driven venture capital investments. | – | fortuniscapital.co.uk | Walton-on-Thames, United Kingdom | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | abbvie.com | Chicago, United States | |
Medical aesthetics products and treatments are provided. | – | allerganaesthetics.com | - | |
A portfolio of generic medicines is developed and manufactured. | 1948 | allergan.com | Madison, United States |
Investor details for Stemson Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Stemson Therapeutics
13 people are tracked at Stemson Therapeutics (3 in leadership, 8 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Geoff Hamilton | Co-Founder & CEO | Leadership |
Alexey Terskikh | Co-Founder & CSO | Leadership |
Alexey V. Terskikh | Co-Founder & Key Scientific Advisor | Leadership |
Michael Rendl | Scientific & Medical Advisor | Board & advisors |
Kapil Bharti | Scientific & Medical Advisor | Board & advisors |
Jenny Rooke | Director | Board & advisors |
Paul Laikind | Independent Director | Board & advisors |
Hideyuki Okano | Scientific & Medical Advisor | Board & advisors |
George F. Murphy | Scientific & Medical Advisor | Board & advisors |
Richard Chaffoo | Scientific & Medical Advisor | Board & advisors |
Paul McAndrews | Scientific & Medical Advisor | Board & advisors |
Sara Abumeri | Research Associate | Team |
Zack Sitte | Scientist | Team |
Complete people profiles for Stemson Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Stemson Therapeutics
3 dated milestones of Stemson Therapeutics across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Stemson Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $15.0M.
Competitors of Stemson Therapeutics
Stemson Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ardelyx, Blue Rock Therapeutics, DermBiont, Aspen Neuroscience and Inozyme Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ardelyx.com | 2007 | Fremont, United States | $61.1M | 37 | Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | |
| bluerocktx.com | 2016 | Boston, United States | $225M | 138 | Stem cell therapies are developed for cardiovascular and neurological diseases. | |
| dermbiont.com | 2015 | Melrose, United States | $78.91M | 14 | Microbial therapeutics for skin diseases are developed. | |
| aspenneuroscience.com | 2018 | San Diego, United States | $224M | – | Provider of genomic-based personalised pluripotent stem cell therapy | |
| inozyme.com | 2016 | Cambridge, United States | $116.4M | 59 | Developer of treatments for rare and debilitating metabolic diseases | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| vedantabio.com | 2010 | Cambridge, United States | $350.49M | 71 | Therapeutics for infectious and autoimmune diseases are developed. | |
| thinkbioscience.com | 2019 | Boulder, United States | $23M | 21 | Synthetic biology platform is utilized to develop small-molecule therapeutics. | |
| ilyapharma.se | 2016 | Uppsala, Sweden | $4.02M | – | Biological drugs for skin and mucosa wound treatment are developed. | |
| qbiotics.com | 2000 | Brisbane, Australia | $98.07M | – | Small molecules from plant extracts are developed for medical applications. |
Detailed competitors of Stemson Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Stemson Therapeutics
The website of Stemson Therapeutics (stemsontx.com) receives about 18.6K visits a month.
- Monthly visits18.6K
▲ 16.8% vs previous month
Websites whose visitors overlap most with Stemson Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
hairsite.com | hairsite.com | 100% | – | #2,678,286 | – |
folliclethought.com | folliclethought.com | 91% | – | #621,236 | – |
Latest news on Stemson Therapeutics
Complete news archive for Stemson Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Stemson Therapeutics
10 companies that operate in the same segment as Stemson Therapeutics (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Stemson Therapeutics
Stemson Therapeutics was founded in 2019.
Stemson Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Geoff Hamilton is the current CEO of Stemson Therapeutics. They have also founded this company.
Stemson Therapeutics is a funded company, having raised a total of $22.5M across 3 funding rounds to date.
Stemson Therapeutics was founded in 2019 in San Diego, United States, within the biotechnology sector. A proprietary platform is utilized to develop stem cell-based therapies for hair growth, focusing on induced pluripotent stem cells (iPSCs) for generating de novo hair follicles and dermal papilla. Operations center on advancing this technology for potential clinical applications in hair restoration.
Stemson Therapeutics's top competitors include Ardelyx, Blue Rock Therapeutics and Aspen Neuroscience.
Stemson Therapeutics has 6 investors. Key investors include AbbVie, Allergan, DCVC, Genoa Ventures, and Allergan Aesthetics.